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https://doi.org/10.1016/j.immuni.2019.04.014SUMMARY
Broadly neutralizing antibodies (bNAbs) against
HIV-1 envelope (Env) inform vaccine design and
are potential therapeutic agents. We identified
SF12 and related bNAbs with up to 62% neutraliza-
tion breadth from an HIV-infected donor. SF12
recognized a glycan-dominated epitope on Env’s
silent face and was potent against clade AE vi-
ruses, which are poorly covered by V3-glycan
bNAbs. A 3.3A˚ cryo-EM structure of a SF12-Env
trimer complex showed additional contacts to Env
protein residues by SF12 compared with VRC-
PG05, the only other known donor-derived silent-
face antibody, explaining SF12’s increased neutral-
ization breadth, potency, and resistance to Env
mutation routes. Asymmetric binding of SF12 was
associated with distinct N-glycan conformations
across Env protomers, demonstrating intra-Env
glycan heterogeneity. Administrating SF12 to HIV-
1-infected humanized mice suppressed viremia
and selected for viruses lacking the N448gp120
glycan. Effective bNAbs can therefore be raised
against HIV-1 Env’s silent face, suggesting their po-
tential for HIV-1 prevention, therapy, and vaccine
development.Immunity 50, 1513–1529, J
This is an open access article undINTRODUCTION
Neutralizing antibodies (NAbs) play a key role in antiviral immu-
nity and are the correlate of protection ofmost available vaccines
(Burton, 2002; Plotkin, 2010). The HIV-1 envelope glycoprotein
(Env) is the only potential target for NAbs on the surface of the vi-
rus (Burton and Hangartner, 2016; Kwong and Mascola, 2018;
Wibmer et al., 2015). Env is a trimeric spike composed of
gp120/gp41 heterodimers that has evolved a plethora of immune
escape mechanisms to evade antibody recognition. These
include instability of the trimer, sparsity of spikes on the virion
surface, high sequence divergence across strains, and epitope
masking through its extensive glycan shield (Burton and Hang-
artner, 2016; Haynes, 2015; Klein and Bjorkman, 2010; Kwong
and Mascola, 2018).
Consequently, effective humoral responses to HIV-1 typically
only emerge several years after infection and only in a subset
of HIV-1-infected individuals (Gray et al., 2011; Landais et al.,
2016; Mikell et al., 2011; Rusert et al., 2016; Tomaras et al.,
2011). Although 50% of chronically HIV-1-infected individuals
develop some degree of cross-clade serum neutralization, only
a small fraction of individuals mounts outstandingly broad and
potent antibody responses against the virus (Doria-Rose et al.,
2010; Hraber et al., 2014; Landais et al., 2016; Rusert et al.,
2016; Sather et al., 2009; Simek et al., 2009). The development
and use of single B cell antibody cloning revealed that this activ-
ity can usually be attributed to one or a combination of broadly
neutralizing antibodies (bNAbs) that target HIV-1 Env (Scheidune 18, 2019 ª 2019 The Authors. Published by Elsevier Inc. 1513
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
et al., 2009a, 2009b, 2011; Walker et al., 2009, 2010; Wu
et al., 2010).
NAbs are proposed to interfere with viral entry in a variety of
ways, including blocking receptor engagement, preventing
membrane fusion, and enhancing decay of Env spikes (Bur-
ton and Hangartner, 2016). Pre-clinical and recent human
studies have highlighted the potential of bNAbs for HIV-1
therapy and prevention (Bar et al., 2016; Bar-On et al.,
2018; Barouch et al., 2013; Caskey et al., 2015, 2017; Gautam
et al., 2016; Julg et al., 2017; Lynch et al., 2015; Mendoza
et al., 2018; Scheid et al., 2016; Shingai et al., 2013). More-
over, structural insights into mechanisms of bNAb binding
have been key to designing novel immunogens and strate-
gies for vaccination (Escolano et al., 2017; Jardine et al.,
2013; Kwong and Mascola, 2018; McGuire et al., 2013;
Sanders et al., 2013; Ward and Wilson, 2017). However, there
remain a number of challenges to the elicitation and clinical
use of bNAbs. For vaccine efforts, these include unusual
structural features of bNAbs such as large insertions/dele-
tions, and/or unusual complementarity determining region
(CDR) lengths as well as extensive somatic hypermutation
(SHM), all of which are rare features in the human repertoire
(Burton and Hangartner, 2016; Haynes and Burton, 2017;
Sok and Burton, 2018). For clinical use of bNAbs, viral
coverage gaps, manufacturability, and pre-existing bNAb
resistance represent potential problems (Escolano et al.,
2017; Gruell and Klein, 2018; Sok and Burton, 2018). Thus,
there is a continuing need to identify bNAbs that may be
more readily elicited by vaccination and that are suitable for
clinical use.
Although many bNAbs have been characterized, their tar-
gets, or ‘‘sites of vulnerability’’, on the HIV-1 Env spike appear
to be limited (Burton and Hangartner, 2016; Kwong and Mas-
cola, 2018; Sok and Burton, 2018; Ward and Wilson, 2017;
West et al., 2014; Wibmer et al., 2015). Numerous monoclonal
antibodies recognize the CD4-binding site, the V3-glycan
patch, the V2-apex, the membrane proximal external region
(MPER), and several epitopes encompassing the gp120-gp41
interface (Burton and Hangartner, 2016; Kwong and Mascola,
2018; Sok and Burton, 2018; Ward and Wilson, 2017; Wibmer
et al., 2015). In contrast, VRC-PG05 is the only donor-derived
antibody isolated to date that binds to the highly glycosylated
‘‘silent face’’ of gp120 (Zhou et al., 2018). However, VRC-PG05
neutralized only 27% of tested HIV-1 strains and had a rela-
tively high mean IC50 of 0.8 mg/mL, leaving uncertain the po-
tential usefulness of this epitope for vaccine design, therapy,
or prevention.
Here, we describe silent face (SF) bNAbs targeting a VRC-
PG05-related epitope that cover up to 62% of evaluated strains
with a mean IC50 of 0.20 mg/mL. To characterize the binding
mechanism of the new antibodies, we determined the 3.1 A˚ crys-
tal of the unbound SF12 Fab and a 3.3 A˚ cryo-EM structure SF12
Fab bound to the clade B B41 Env trimer. We found that SF12
binds the center of the Env silent face with a different orientation
and set of contacts than VRC-PG05. The overall breadth and
potency achieved by SF12 suggests that the silent face is an
additional target for vaccine design and that antibodies to this
site may be clinically useful as a complement to other avail-
able bNAbs.1514 Immunity 50, 1513–1529, June 18, 2019RESULTS
Isolation of an Antibody Family from Donor 27845 by B
Cell Culture and BG505 Sorting
Donor 27845was diagnosedwith HIV-1 in 1985 and followed in a
cohort of long-term non-progressors at the Fred Hutchinson
Cancer Research Center from 1998–2006. Apart from an inter-
ventional study during which the subject started and stopped
anti-retroviral therapy (ART) at set intervals from 1998–2001,
the subject has been off ART (Figure 1A). The individual’s purified
immunoglobulin G (IgG) isolated from a 2005 time point was
evaluated for neutralization against a 12-virus panel representa-
tive of the global epidemic (deCamp et al., 2014) (Figure 1B) and
found to be both broad and potent with a coverage of 92% and
an average median inhibitory concentration (IC50) of 92.3 mg/mL
(Figure 1B). To inform potential antibody isolation strategies,
neutralization fingerprinting of the subject’s IgG was performed,
but the results were inconclusive due to borderline prediction
confidence scores (Doria-Rose et al., 2017) (Figure 1B).
Based on the fingerprinting results, we employed an unbiased
B cell microculture approach for antibody cloning (Doria-Rose
et al., 2015; Huang et al., 2013). From a starting number of
4.4 3 104 memory B cells, we identified seven B cells, six of
which were members of a single clone, that showed potent
anti-HIV-1 neutralizing activity against two indicator strains.
Subsequent single B cell sorting using fluorescently labeled
BG505.SOSIP.664 native-like Env trimers (Sanders et al., 2013)
yielded two additional members of this antibody family, one of
which was identical to an antibody obtained in the B cell culture.
The members of the clone utilized VH4-59*01 and VK3-20*01
heavy and light chain variable gene segments and included
CDRH3s and CDRL3s of 23 and 6 amino acids, respectively
(Table S1). VH gene segment mutation frequencies ranged
from 17%–25% of nucleotides (21%–39% amino acids), and
VK gene segment mutation frequencies ranged from 15%–21%
of nucleotides (20%–29% amino acids), intermediate rates
of SHM for HIV-1 bNAbs (Table S1). Based on heavy chain
sequences, the family segregated into three phylogenetic
branches (Figure 1C), with the SF5/SF12 branch showing a
three-nucleotide CDRH2 insertion.
When tested on two representative panels of 20 (f61 panel)
and 12 (global panel) viruses (deCamp et al., 2014; Doria-
Rose et al., 2017), members of the VH4-59 clone showed diverse
levels of activity and breadth (Figure 1D). Two closely related
members of the VH4-59 clone that were the most active, SF5
and SF12, were then evaluated against a 119-virus panel repre-
sentative of all major circulating HIV-1 clades (Figure 1E; Table
S2) (Freund et al., 2017; Mouquet et al., 2012). SF5 and SF12
neutralized 58% and 62% of viruses in this larger panel, with
geometric mean IC50s of 0.25 and 0.20 mg/mL, respectively.
Notably, SF12 neutralized all of 18 tested clade AE viruses
across the three panels and showed a pattern of neutralizing
activity that differed from previously described bNAbs (Fig-
ure 1F). Overall, the antibody clone recapitulated the majority
of the polyclonal IgG neutralization activity, with the potency
correlation between isolated monoclonal antibodies (mAbs)
and donor 27845’s IgG resembling those of other elite neutral-
izers from whom we previously isolated bNAbs (Freund et al.,
2017; Scheid et al., 2011).
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Figure 1. Isolation of Antibody Family from Donor 27845 by B Cell Culture and BG505 Sorting
(A) Viral loadandCD4+ T cell counts ofHIV-1-infected subject 27845over time.Arrows indicate timepoints ofB cellmicroculture andBG505.SOSIP.664bait-sorting.
(B) Neutralization data of donor 27845’s serum IgG in 2005 against a 12-virus cross-clade panel (global) and a 20-virus fingerprinting panel (f61). Shown are
median inhibitory concentrations (IC50) in mg/mL. On the right, fingerprinting analysis of f61 serum neutralization. Neutralization testing performed in duplicates,
average shown.
(C) Maximum-likelihood phylogenetic tree of heavy chain sequences of newly isolated antibody family. MC = Antibodies isolated by B cell microculture, BG505-
sort = antibodies isolated by bait-sorting, Both = antibody found both by microculture and bait-sorting.
(D) Neutralization of isolated antibody family members (IC50) against global and f61 virus panels. Legend as in (B). Neutralization testing performed in duplicates,
average shown.
(E) Neutralization coverage and potency of SF5 and SF12 on a 119-virus cross clade panel. Neutralization testing performed in duplicates, average shown.
(F) Neutralization fingerprinting of SF5 and SF12 in comparison to other known anti-HIV-1 bNAbs.
See also Figure S1 and Tables S1 and S2.We next evaluated potential autoreactivity and polyreactivity
of SF12 and SF5 using HEp-2 staining (Haynes et al., 2005)
and a baculovirus-based polyreactivity assay (Ho¨tzel et al.,2012), respectively (Figure S1). In contrast to bNAbs with known
autoreactive and polyreactive properties such as 2F5 and 4E10
(Haynes et al., 2005), we found minimal to no autoreactivity orImmunity 50, 1513–1529, June 18, 2019 1515
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Figure 2. Antibodies SF5 and SF12 Bind a Distinct Epitope on the gp120 Portion of Env
(A) ELISA of SF5 and SF12 against a gp120 monomer and a gp140 foldon trimer derived from HIV-1 strain YU2. Wild-type proteins and various site mutants of the
proteins in common bNAb epitopes (CD4-binding site, V3-glycan, Apex) were tested. Triple mutant = N160K, A281T + D368K, N332K. Data representative of 3
repeat assays.
(B) ELISA of SF5 and SF12 as well as reference bNAbs targeting 6 known epitopes against the BG505.SOSIP.664 trimer. Data representative of 3 repeat assays.
(C) Competition ELISA with reference bNAbs targeting 6 known epitopes to evaluate interference with SF5 and SF12 binding to the BG505.SOSIP.664 trimer.
Competing antibodies were added in a dilution series starting at 32 mg/mL. SF5 and SF12 were added at a constant concentration of 0.5 mg/mL. Data repre-
sentative of 3 repeat assays.
(D) Neutralization testing of SF12 against a panel of YU2 site mutants covering major epitopes on the HIV-1 spike. Neutralization testing performed in duplicates,
average curves shown.
(E) Computational analysis of 119-virus cross clade panel neutralization.
(F) Neutralization testing of SF5 and SF12 against an HIV-1 pseudovirus based on strain YU2 carrying a mutation at the PNGS N448gp120. Testing done in
duplicates, average shown.polyreactivity for SF5 and SF12 (Figures S1A and S1B). In addi-
tion, the pharmacokinetics of SF12 in mice were similar to those
of 3BNC117, a bNAb that exhibits a typical IgG1 half-life in ma-
caques (Gautam et al., 2016) and humans (Caskey et al., 2015)
(Figure S1C). We conclude that the SF antibody family achieves
substantial anti-HIV-1 neutralization with an intermediate degree
of somatic hypermutation and no evidence for autoreactivity.1516 Immunity 50, 1513–1529, June 18, 2019Antibodies SF5 and SF12 Bind a Distinct Epitope on the
gp120 Portion of Env
To map the epitope recognized by SF5 and SF12, we performed
ELISAs using HIV-1 Env proteins. Both antibodies bound to
monomeric YU2 gp120, indicating that a portion of the epitope
is contained within the gp120 subunit of Env (Figure 2A). We sub-
sequently evaluated ELISA binding to site-directed mutants in
monomeric YU2 gp120 and an uncleaved YU2 gp140 foldon
trimer (Yang et al., 2000) that define common epitopes. Mutation
of the CD4-binding site (D368R/D368Kgp120, A281Tgp120) (Dose-
novic et al., 2015; Horwitz et al., 2013; Olshevsky et al., 1990), the
V3 glycan patch (N332A/N332Kgp120) (Horwitz et al., 2013; Mou-
quet et al., 2012), and the V2 apex epitope (N160Kgp120) (Walker
et al., 2009), alone or in combination, did not abrogate SF5 or
SF12 binding (Figure 2A). SF5 and SF12 also bound to a cleaved
soluble native-like BG505.SOSIP.664 trimer (Sanders et al.,
2013) (Figure 2B). Taken together, these results suggested that
SF5 and SF12 bind an epitope that is present on gp120 mono-
mers and both cleaved and uncleaved Env trimers.
We performed competition ELISAs to assess binding to the
BG505.SOSIP.664 trimer using antibodies targeting the CD4-
binding site (3BNC117, 8ANC131), the V3 glycan patch (10-
1074), the V2-apex (PGDM1400) and the gp120-gp41 interface
(8ANC195, PGT151 and 35O22). Both SF5 and SF12 competed
strongly with themselves and each other (Figure 2C). 3BNC117,
a CD4-binding site antibody that bridges adjacent protomers
within a trimer and has a broad contact surface with gp120
(Lee et al., 2017), showed competition with both SF5 and
SF12. Incomplete competition was also observed for the CD4-
binding site antibody 8ANC131 and for the gp120-gp41 interface
antibodies 8ANC195 and PGT151. Moreover, the V3-glycan tar-
geting antibody 10-1074 competed strongly with SF5 but not
with SF12 (Figure 2C). We also assessed the neutralizing activity
of SF12 on a YU2 pseudovirus mutant panel comprising a num-
ber of mutations that impair the activity of CD4-binding site, V3-
glycan and V2-apex antibodies using a TZM.bl-based in vitro
neutralization assay. SF12 neutralizing activity was insensitive
to the mutations, including a triple mutant carrying mutations in
all three epitopes (N280Ygp120, N160Kgp120, N332Kgp120) (Fig-
ure 2D). These data indicate that SF5 and SF12 bind a distinct
epitope near the epitopes for CD4-binding site bNAbs and
gp120-gp41 interface bNAbs 8ANC195 and PGT151.
Computational analysis (West et al., 2013) of available neutral-
ization data suggested that SF5/SF12 depend on the presence of
a glycan at N448gp120 (Figure 2E). To verify that the neutralizing
activity of SF5 and SF12 depended on this potential N-linked
glycosylation site (PNGS), we showed that these antibodies failed
to neutralize a mutant HIVYU2 pseudovirus lacking the N448gp120
glycan (Figure 2F). The PNGS at position 448gp120 is at the center
of one of the most highly glycosylated parts of the HIV-1 trimer,
also known as the silent face (Wyatt et al., 1998). Although
comparisons of synonymous versus non-synonymous mutations
suggested that the silent face is under immunologic pressure
(Stewart et al., 2001), antibodies that bind to the center of this
region have been difficult to isolate. Indeed, VRC-PG05 repre-
sented an, until now, unique example of a host-derived bNAb
that specifically targets the center of the silent face with a focus
on the glycan site at N448gp120 (Zhou et al., 2018). The discovery
and characterization of SF12 and related silent face bNAbs
shows that this epitope can be targeted by antibodies with
greater breadth and potency than VRC-PG05.
Structure of the Natively Glycosylated SF12-Env
Complex
We determined a 3.1 A˚ crystal structure of the SF12 Fab and a
3.3 A˚ cryo-EM structure of a natively glycosylated clade B B41SOSIP.664 trimer in complex with the SF12 Fab and a Fab
from the V3/glycan patch bNAb 10-1074 (Figures 3A and 3B).
Although 10-1074 Fab normally binds with a 3:1 Fab:Env trimer
stoichiometry (Gristick et al., 2016), EM class averages showed
either three or two SF12 Fabs bound to the Env trimer and only
one 10-1074 Fab (Figures S2 and S3). Like VRC-PG05, for which
a crystal structure was solved in complex with a monomeric
gp120 core (Zhou et al., 2018), the SF12-trimer complex reveals
recognition of an epitope focused on the N262gp120, N295gp120,
and N448gp120 glycans on the silent face of Env, rationalizing our
binding and in vitro neutralization results (Figures 2A–2F). Super-
imposition of the free and Env-bound SF12 Fab structures
showed only minor conformational changes resulting from Env
glycan interactions with the SF12 Fab in the Env-bound struc-
ture, as evidenced by the 1.1 A˚ root-mean-square deviation
(RMSD) relating 245 Ca atoms in the VH and VL domains of the
free and bound Fabs (Figure 3C).
We found three distinct differences between the structures of
a VRC-PG05 Fab-monomeric CNE55 gp120 core and the SF12-
Env trimer complexes (Zhou et al., 2018). First, the longer CDRH3
of SF12was extended in a different conformation from that of the
shorter CDRH3 in VRC-PG05, resulting in a RMSD of 3.1 A˚
across 130 Ca atoms when superposing the VH domains from
the Fab-bound structures (Figure 3C). Second, the SF12
CDRL1 and CDRL3 loops adopted conformations different
from those of their VRC-PG05 counterparts (Figure S4). In the
SF12 Fab, the CDRH3 and CDRL loops form a groove at the
Fab-antigen interface that accommodates the N448gp120 glycan,
which contrasts with the wedge between the VRC-PG05 CDRH3
and CDRL1 loops that penetrates through Env glycans (Figures
3D and 3E). Third, the orientation of the SF12 Fab differed from
that of VRC-PG05 Fab, with the SF12 Fab exhibiting an almost
perpendicular binding angle to the silent face epitope compared
with the VRC-PG05 orientation (Figures 3F and S4). To evaluate
this difference, we calculated the rotation and translation of the
VH-VL domains of the Fab portions of the SF12-Env trimer and
VRC-PG05-gp120 complex structures, finding that the orienta-
tions of the SF12 and VRC-PG05 VH-VL domains differed, with
the axis of the SF12 Fab at a steeper angle (by71) to the silent
face epitope than the axis of VRC-PG05. Despite differences
in approach angles to the silent face epitope, SF12 and
VRC-PG05 shared a common mode of interaction with the
N448gp120 glycan, mediated in each case by their CDRH3 loops
(Figure 3G). We conclude that SF12 binds a VRC-PG05-related
epitope with a different angle of approach and an altered mode
of recognition from VRC-PG05.
SF12 Recognizes a Mostly Glycan-Focused Epitope on
HIV-1 Env
In contrast to the non-natively glycosylated monomeric CNE55
gp120 core that was complexed with VRC-PG05 Fab (Zhou
et al., 2018), the relatively high resolution cryo-EM structure of
the natively glycosylated SF12-Env trimer complex allowed
modeling of N-linked glycans in the B41 Env trimer (Figure 3).
Given the asymmetric Fab binding in our complex, we character-
ized the SF12 epitope and paratope using a gp140 protomer in
which the SF12, but not the 10-1074, Fab was bound (Figures
4A–4C). Consistent with differing binding angles and CDR loop
conformations, SF12’s footprint on Env differed from that ofImmunity 50, 1513–1529, June 18, 2019 1517
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Figure 3. Structural Overview of the SF12-B41-10-1074 complex
(A and B) Side-view (A) and top-view (B) of the final 3.3 A˚ single-particle cryo-EM reconstruction of the SF12-B41-10-1074 complex colored by components (dark
gray, gp41; light gray, gp120; magenta, SF12 VH; pink, SF12 VL; blue, 10-1074 VH; light blue, 10-1074 VL; cyan, N-glycans).
(C) Superposition of VH-VL domains (235 Ca atoms) of unliganded SF12 (orange), Env-bound SF12 (magenta), and core gp120-bound VRC-PG05 (green) Fabs,
showing differences in CDR conformations between SF12 and VRC-PG05.
(D) Surface representation of SF12 (magenta/pink) and VRC-PG05 (green/pale green) Fabs illustrating differences in CDRL1 and CDRH3 loop conformations.
(E) Surface representation of Env-bound SF12 Fab showing interactions with the N262gp120 (pale blue), N295gp120 (pale green) and N448gp120 (red) glycans at the
SF12-Env interface. Cryo-EM density for individual glycans is shown contoured at 6s.
(F) Comparison of VH-VL domain orientations of SF12 (magenta/pink; cartoon) and VRC-PG05 (green/pale green; surface). The VH-VL domain orientation of SF12
on Env trimer is related by a 71 rotation and 0.5 A˚ translation to the VRC-PG05 variable domains after alignment against gp120 (gray; surface).
(G) Overlay of CDRH3 loops of SF12 (magenta) and VRC-PG05 (green) after alignment of bound gp120s illustrates CDRH3-mediated recognition of the N448gp120
glycan (red; sticks) by both antibodies.
See also Figures S2, S3, and S4 and Tables S3 and S4.
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Figure 4. Details of SF12 Epitope and Glycan Recognition
(A) Sequence of SF12 variable domainswith antibody regions annotated using IMGT sequence analysis (CDR loops are bracketed). SF12 residues that contact N-
linked glycans are in blue (N262gp120), green (N295gp120), and red (N448gp120), while gp120-contacting residues are boxed. Contacting residues in the SF12
paratope and epitope were defined as two residues containing any atom within 4 A˚ of each other.
(B) Structure of a SF12-B41 gp120 protomer from the trimer complex, showing paratope residues as spheres (inset). Color scheme is the same as in (A).
(C) Surface representation of B41 trimer, with SF12 epitope highlighted in magenta.
(D–F) Stick representation of residue level contacts for N262gp120 (D), N295gp120 (E), and N448gp120 (F) glycans. Potential hydrogen bonds are shown as black
dashes. Cryo-EM density maps contoured at 6s are shown for individual glycans.
See also Figure S4 and Table S5.VRC-PG05, such that interactions with both N-linked glycan and
peptide components mapped almost exclusively to the SF12
heavy chain (Figures 4A–4C). For example, 7% of the buried
epitope surface resulted from interactions with SF12’s light chain
(1,843 A˚2 buried surface area (BSA) of epitope against SF12
heavy chain versus 135 A˚2 against the SF12 light chain; Table
S5), compared with36% of buried epitope surface at the VRC-
PG05 light chain interface. This difference is likely due to thelonger CDRL1 and L3 loops on VRC-PG05, which penetrate
the glycan-rich epitope (Figures 3C and 3D).
In the Env protomer used for epitope analysis, we interpreted
densities for an ordered GlcNAc2Man7 at N262 gp120, a GlcNAc2
Man6 at N295gp120, and a GlcNAc2Man5 at N448gp120 (Figures
4D–4F). Similar to VRC-PG05, the N262gp120, N295gp120, and
N448gp120 glycans constituted 75% of the epitope surface
(Table S5), although comparisonsmust be interpreted cautiouslyImmunity 50, 1513–1529, June 18, 2019 1519
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Figure 5. SF12 Engages Two Distinct
Regions of gp120 Peptide Epitope
(A) Stick representation of SF12 CDRH3 (magenta)
and gp120 (gray) contacts at the SF12-Env inter-
face. Trp100DHC inserts into a hydrophobic
pocket (inset) stabilized by potential hydrogen
bond interactions (black dashes) with neighboring
residues.
(B) Stick representation of SF12 CDRH1 and H2
residues (magenta) contacting gp120 residues
(gray). Potential hydrogen bonds are shown as
black dashes. Density maps for SF12 and gp120
residues are shown as magenta and gray meshes,
respectively, contoured at 8s.
(C) Comparison of SF12 and VRC-PG05 neutrali-
zation breadth for different viral characteristics.
The red dashed line indicates neutralization
breadth for SF12 (62%) and VRC-PG05 (27%)
against a cross-clade panel.
(D) Modeling of the N442gp120 glycan from clade C
426c SOSIP trimer (teal; PDB: 6MYY) was ach-
ieved by aligning gp120 coordinates from the two
structures. Potential clashes with SF12 heavy
chain (magenta) regions are highlighted.
See also Figure S5.due to (1) the use of a highmannose-only monomeric gp120 core
for the VRC-PG05 complex structure (Zhou et al., 2018) versus a
natively glycosylated native-like Env trimer for the SF12 complex
structure, and (2) the higher resolution (2.4 A˚) of the VRC-PG05-
gp120 crystal structure than that of the SF12-Env trimer cryo-EM
structure (3.3 A˚). Mapping key residues involved in SF12-Env
interactions identified determinants of glycan recognition medi-
ated by specific regions in the SF12 paratope. For example,
SF12’s CDRH1 and framework region 3 (FWR3) interacted exclu-
sively with the N295gp120 glycan, while CDRH2 solely engaged
the N262gp120 glycan (Figures 4D and 4E). SF12 interactions
with the N448gp120 glycan were mediated mainly by CDRH3,
with additional contacts observed with the light chain CDRL1
and CDRL3 loops (Figure 4F).
Because the frequency of SHM in SF12 is lower than typical
for many HIV-1 bNAbs (Figure 1E; Table S1), we analyzed the
contributions of mutated amino acid residues in the SF12 para-
tope to epitope recognition. Of the 17 V gene segment-en-
coded residues that contact the epitope, 9 arose through
SHM, including an insertion in CDRH2 (Figure S5A). Consistent
with glycans comprising most of the SF12 epitope, SHMs were
mostly observed for residues at the antibody-glycan interface.
However, unlike VRC-PG05, where SHMs mainly resulted in
the removal of bulky tyrosine residues to accommodate gly-
cans (Zhou et al., 2018), SF12 utilized tyrosines, as well as
bulky hydrophilic residues, to facilitate interactions with the1520 Immunity 50, 1513–1529, June 18, 2019glycopeptide epitope (Figure S5). This
demonstrates that SHMs adding bulky
residues to the paratopes of antibodies
against the glycan-rich silent face of
HIV-1 Env are not necessarily an imped-
iment to broad and potent neutraliza-
tion by these antibodies (Figures 4D–4F
and S5A).The protein component of the SF12 epitope (25% of the
epitope surface) mapped to two regions of gp120 (Figures 5
and S4). The first region involved residues from the gp120 b4
and b7 strands and the N terminus of gp120 that were engaged
by regions of CDRH3 that penetrated the glycan shield (Fig-
ure 5A). In this interaction, SF12 CDRH3 residues R100CHC
and D100BHC formed potential hydrogen bonds with Env resi-
dues K59gp120 and R252gp120, respectively (Figure 5A). These
interactions contributed to the formation of a hydrophobic
pocket on gp120 into which SF12 residue Trp100DHC inserted,
shielding this exposed hydrophobic residue at the tip of the
CDRH3 loop (Figure 5A, inset). The second protein component
of the SF12 epitope resembled part of the VRC-PG05 gp120
protein epitope, involving residues from gp120 b12 and b22
that interacted with the SF12 CDRH1 and H2 loops (Figure 5B).
In this region, SF12 utilized aspartates at positions 30HC and
54HC to mediate contacts with gp120 residues N295gp120,
R444gp120, and S446gp120 (Figure 5B). Unlike VRC-PG05,
SF12 directly engaged the protein component of the epitope,
forming extensive hydrogen bonds with surrounding residues.
The increased epitope surface area contributed by gp120 pep-
tide components (25% for SF12 versus 12% for VRC-PG05)
likely contributes to the observed differences in neutralization
potency and breadth for the two antibodies (Figure 1E). Overall,
our structure of SF12 bound to a natively glycosylated Env
trimer allows detailed insights into SF12 Env-glycan interactions
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Figure 6. SF12-B41-10-1074 Structural
Asymmetry Is Explained by N295gp120
Glycan Heterogeneity
(A) Comparison of cryo-EM density for N295gp120
(green) and N332gp120 (orange) glycans across
protomers within the SF12-B41-10-1074 trimer
complex. In each protomer, SF12 (magenta) was
bound, but 10-1074 (blue) binding was only
observed when the N295gp120 glycan was
modeled as GlcNAc2 (right panel).
(B) Overlay of N295gp120 and N332gp120 glycans
after aligning gp120 protomers from cryo-EM
structures of SF12-B41-10-1974, PDB: 6CUE,
PDB: 6DCQ, PDB: 5V8M, and PDB: 6CRQ. Posi-
tions for the N295gp120 and N332gp120 glycans in
the SF12-bound Env (stick representation) and all
other models (line representation) are shown.
SF12-induced conformational changes are indi-
cated by the red arrow.
(C) Modeling of the 10-1074 Fab (blue cartoon)
onto the SF12-gp120 protomer (A: left panel).
Potential clashes between 10-1074 CDRH3 and
the N332gp120 glycan are highlighted.
(D) Alignment of gp120 portions of the SF12-
bound (A: left panel) and SF12 plus 10-1074-
bound (A: right panel) protomers. Potential clashes
involving the N295gp120 and N332gp120 glycans
(highlighted stars) when both glycans are pro-
cessed beyond a core pentasaccharide are
shown.
(E) Predictive neutralization profiles for combina-
tion therapy with SF12 and 10-1074 bNAbs at a
10 mg/mL concentration.
See also Figure S5 and Tables S6 and S7.and demonstrates that SF12 forms more extensive protein con-
tacts with Env than VRC-PG05.
Resistance to SF12 Is Driven by Glycan Contacts
To confirm our structural findings and assess possible mecha-
nisms of resistance to SF12 and SF5 neutralization, we created
a series of mutant BG505 and YU2 pseudoviruses and evaluated
their sensitivity to neutralization in TZM.bl assays. Disruption of
the PNGS at N448gp120 (N448K, N448S) or N262gp120 (N262S,ImmN262W) abrogatedSF5andSF12 neutral-
ization (Table S6). In contrast, removal of
the glycan at 295gp120 slightly improved
neutralization by both SF5 and SF12
for the BG505 and YU2 strains, indicating
that these antibodies accommodate,
rather than make favorable contacts
with, the glycan at N295gp120. This result
was consistent with neutralization data
against strains lacking the N295gp120
glycan (Table S7) and the SF12-B41 com-
plex structure, as one gp140 protomer in
the trimer showed density for GlcNA2 at
the N295gp120 glycan despite the pres-
ence of bound SF12 Fab (Figure 6A).
To explore protein-protein interactions
at the SF12-Env interface, we examinedmutations in positions 214gp120 (P214I, P214Q), 291gp120
(S291P, S291T), 293gp120 (Q/V293E, Q/V293K, Q/V293R), and
444gp120 (R444T) in the Envs of the BG505 and YU2 pseudovi-
ruses.UnlikeVRC-PG05,whereadominantmeans toescapeanti-
bodyneutralizationwasachievedbymutatingE293gp120 todisrupt
a critical contact with VRC-PG05’s CDRL1 and CDRH3 loops
(Zhou et al., 2018), analysis of SF12 neutralization potency against
the mutant pseudoviruses showed that SF12 remained potent
against pseudoviruses with E293gp120 substitutions (Figure 5C;unity 50, 1513–1529, June 18, 2019 1521
Tables S6 and S7). A 2-fold decrease in sensitivity to SF12 was
observed for the R444T mutation, likely due to disruption of a
hydrogen-bonding network between Env residue R444gp120 and
SF12 residues D30HC and D54HC. Env mutations at positions
214gp120 and 293gp120 preferentially affected the SF5 clonal
variant, which is less potent than SF12. Effects due to mutations
at the 293gp120 residue in both BG505 and YU2 backbones are
likely explained by the presence of R31HC in the SF5 CDRH1,
which would directly engage with residue E293gp120 (Figure S5B).
Interestingly, a threonine at position 444gp120 is a strong pre-
dictor of resistance to SF12/SF5 neutralization, consistent with
increased activity against clade AE and B viruses, which show
a <1% frequency for a threonine at this position (Figure 5C; Table
S7). Computational analysis of viral strains containing residue
T444gp120 (37% of 3260 Env sequences in Antibody Database)
(West et al., 2013) showed that 78% of the T444gp120-containing
sequences included an asparagine at position 442gp120 to create
a 442gp120 PNGS. To determine whether a glycan at position
N442gp120 would disrupt SF12 binding, we modeled coordinates
for the N442gp120 glycan from the clade C 426c DS-SOSIP struc-
ture (Borst et al., 2018) after superposing the PDB 6MYY gp120
onto the gp120 of our Env trimer structure and adding in the
N442gp120 glycan. In the conformation observed on the 426c
Env structure, theN442gp120 glycanwould clashwith SF12 heavy
chain CDRH1 and FWR3 components, sterically hindering ac-
cess to its epitope (Figure 5D). This likely explains SF12/SF5’s
decreased breadth and potency against clade C viruses, 85%
of which encode T444gp120 (Table S7). However, binding of
SF12 could shift the position of the glycan, as seen for the
N295gp120 glycan (Figures 6A and 6B), since SF12 shows
neutralizing activity against some N442gp120 glycan-containing
viruses (Table S7). Our results indicate that resistance to SF12/
SF5 is mediated mainly through mutation of N-glycan sites,
rather than Env protein residues, as seen for VRC-PG05.
Heterogeneity of Glycan N295 Explains SF12-Env
Complex Asymmetry
Given that previous V3-targeting bNAb structures showed sym-
metric binding of three V3-glycan patch Fabs per trimer (Ward
and Wilson, 2017), including a recent cryo-EM structure of a
BG505 DS-SOSIP bound by three PGT122 Fabs (Dingens
et al., 2018), we sought to understand the asymmetric binding
of the V3-directed 10-1074 Fab in the SF12-B41-10-074 struc-
ture (Figures 3A and 3B), noting that potential Env trimer
asymmetry could not have been detected in the VRC-PG05
Fab-CNE55 complex structure, which was solved using a mono-
meric gp120 core (Zhou et al., 2018). Because asymmetric bind-
ing of SF12 and 10-1074 Fabs to the B41 Env trimer prevented
the use of symmetry restraints during reconstruction and model
building, density for each glycan at a PNGS was interpreted
independently across gp140 protomers. Interestingly, glycan
heterogeneity was observed at the N295gp120 glycan, which
correlated with the presence or absence of the 10-1074 Fab
(Figure 6A).
Alignment of SF12-bound gp120 protomers in the absence
and presence of 10-1074 Fab (Figure 6A, left and right panels,
respectively), revealed a low (<0.2 A˚) RMSD for 452 gp120 Ca
residues, suggesting that the lack of 10-1074 binding was not
due to alteration in the protein portion of the V3 epitope. Howev-1522 Immunity 50, 1513–1529, June 18, 2019er, the N332gp120 glycan exhibited an altered conformation in the
SF12-gp140 protomers without a bound 10-1074 Fab. Indeed,
superposition of gp120 coordinates from cryo-EM structures
that included coordinates for the N295gp120 and N332gp120 gly-
cans showed that SF12 binding induced conformational
changes that resulted in the N332gp12i0 glycan occluding the
underlying protein portion of the V3-glycan patch epitope
(Figure 6B). This conformation for the N332gp120 glycan would
prevent 10-1074 binding due to steric clashes (Figure 6C). More-
over, the N295gp120 glycan conformation in the SF12-bound Env
protomer and the N332gp120 glycan conformation in the 10-
1074-bound Env protomer would be incompatible if both
glycans were present in fully processed forms (Figure 6D). Taken
together, this explains why a 10-1074 Fab could be accommo-
dated on one protomer in our trimer complex, because the
N295gp120 glycan appeared to be under-processed in the
10-1074-bound protomer (GlcNAc2 versus GlcNAc2Man6
observed in the other protomers).
Moreover, Fab interactions with the N295gp120 glycan likely
explains observed differences in SF12 and SF5 binding proper-
ties, as SF5, but not SF12, was strongly competed by 10-1074 by
ELISA (Figure 2B). SF5 includes a tyrosine in heavy chain FWR3
(Y77HC), which arose through SHM to engage the core GlcNAc2
of theN295gp120 glycan (Figure S5C). It is possible that during ac-
commodation of 10-1074 binding, movement of the N295gp120
glycan toward SF5 Fab would clash with Y77HC, compared to
the less bulky N77HC in SF12 (Figure S5D). Despite the possibility
for incompatible modes of binding to the same Env protomer
with fully processed N-linked glycans at 295 and 332, SF12
and 10-1074 delivered as combination therapy could potentially
achieve 90% breadth, as their neutralization patterns comple-
ment each another (Figure 6D). In sum, our SF12-Env trimer
structure revealed N-glycan heterogeneity across different pro-
tomers of the same trimer, which was associated with differential
binding to bNAbs.
Evaluation of SF12 in HIV-1-Infected Humanized Mice
We assessed the in vivo anti-HIV-1 activity of SF12 in humanized
mice. Results from studies in mice are relevant to humans
because clinical trials of HIV-1 bNAbs administered to infected
patients showed that viral escape mutations are similar, if not
identical, to those found in HIV-1-infected humanized mice
(Bar-On et al., 2018; Caskey et al., 2015, 2017; Horwitz et al.,
2013; Klein et al., 2012; Mendoza et al., 2018; Scheid et al.,
2016). Mice were infected with HIV-1YU2 (Zhang et al., 2002)
(n = 7) and subcutaneously administered 1 mg of SF12 IgG fol-
lowed by 0.5 mg of SF12 every 3 days for 3 weeks. Untreated
HIV-1YU2-infected mice (n = 7) with comparable viral loads and
matched stem cell donors served as controls. Mice treated
with SF12 showed an average drop in viremia of 0.68 log10
copies/mL (range: 0.13–1.87 log10 copies/mL) with viral rebound
occurring within 3 weeks after initiation of therapy (Figure 7A). To
document escape mutations, single genome sequencing of
gp160 was performed on mouse plasma samples 4 weeks after
initiation of SF12 therapy. Of 29 independent isolates from 4
SF12-treated mice, we found mutations that abrogated the
PNGS at position N448gp120 in 28 sequences (97%). These mu-
tations exclusively affected position 448gp120 and mutated the N
at position 448gp120 to K, S, D, or I through single nucleotide
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Figure 7. In Vivo Evaluation of SF12 IgG in HIVYU2-Infected Humanized Mice
(A) SF12 monotherapy of humanized mice infected with HIVYU2. The left graph shows absolute viremia (y axis) in mice treated with SF12 (n = 7, dark gray, full
circles) or untreated control mice (n = 7, empty circles) over the course of the experiment (x axis, days). Mice were infected 3 weeks prior to therapy initiation and
received 1mg of IgG as a loading dose followed by twice-weekly administration of 0.5 mg for 3 weeks. The dotted line at bottom indicates the limit of accuracy of
the qPCR assay (384 copies/mL). The right graph shows relative log drop after initiation of SF12 therapy (Dlog10 copies/mL). Thick red lines and thick dashed gray
lines indicate the mean viral load of treated and untreated mice, respectively. Data from one independent experiment.
(B) Amino acid alignment of gp160 of wild-type YU2gp160 (top) with Env gp160 sequences obtained by single genome sequencing from plasma of SF12-treated
mice 4 weeks posttherapy initiation. Each line represents one sequence; mouse identification numbers indicated on left.
(C) Pie chart showing the amino acid distribution at position N448gp120 in mice that received SF12 at 4 weeks posttherapy initiation. Numbers inside pie chart
correspond to number of mice sequenced/number of sequences obtained.
(D) Antibody tri-mix (SF12, 10-1074, 3BNC117) therapy of HIV-1YU2-infected mice (n = 8). Mice (n = 4) with comparable viral loads and matched stem cell donors
served as controls. Data from one independent experiment. Graphs as in (A).changes, with the mutation to K being most frequent (Figures 7B
and 7C). We conclude that antibody SF12 can reduce viremia
and exerts strong selective pressure on HIV-1 in vivo.
While antibody therapy with two effective bNAbs (PG16,
NIH45-46G54W) failed to mediate long-term viral suppression
(Klein et al., 2012), a triple antibody regimen comprising
3BNC117, 10-1074, and PG16 suppressed viremia in infectedhumanizedmice for several weeks (Horwitz et al., 2013). To deter-
mine whether SF12 can contribute to control of viremia in human-
ized mice as part of a triple combination regimen, we treated
HIV-1YU2-infected mice (n = 8) with a tri-mix of bNAbs SF12,
10-1074, and 3BNC117. Mice (n = 4) with comparable viral loads
andmatched stem cell donors served as controls. Mice receiving
tri-mix therapy dropped 1.36 log10 copies/mL (range: 0.38–2.05Immunity 50, 1513–1529, June 18, 2019 1523
log10 copies/mL) during the 5 weeks of treatment. During the
observation period, viremia was suppressed in all but one of
the treated mice (Figure 7D). Thus, a triple antibody combination
regimen that includes SF12 to restrict overall viral escape can
mediate long-term control of HIV-1YU2 viremia in vivo.
DISCUSSION
Anti-HIV-1 bNAbs can control and prevent HIV-1 infection in hu-
manized mice and macaques (Baba et al., 2000; Barouch et al.,
2013; Hessell et al., 2009a, 2009b; Klein et al., 2012, 2014; Mas-
cola et al., 2000; Shingai et al., 2013, 2014). In addition, bNAbs
against two epitopes, the CD4-binding site and the V3-glycan
patch, have been evaluated in humans: the antibodies were
well-tolerated, exhibited typical IgG half-lives, andwere effective
in lowering viremia and preventing viral rebound in subjects un-
dergoing analytical treatment interruption (Caskey et al., 2015,
2017; Lu et al., 2016; Lynch et al., 2015; Mendoza et al., 2018;
Scheid et al., 2016; Schoofs et al., 2016). Anti-viral effects of
bNAbs in pre-clinical models and humans are mediated by a
combination of virus neutralization and Fcg receptor-mediated
elimination of infected cells (Halper-Stromberg et al., 2014; Hes-
sell et al., 2007; Lu et al., 2016), highlighting the potential of Fc
effector functions as modulators of bNAb efficacy. Fc-modified
bNAb variants with increased affinity for the neonatal Fc receptor
showed half-lives of more than 70 days in humans (Gaudinski
et al., 2018), suggesting that passive administration of anti-
HIV-1 bNAbs may be a practical therapeutic strategy.
However, administration of individual bNAbs, like monother-
apy with anti-retroviral drugs, leads to emergence of resistant
viral variants. In contrast, combinations of bNAbs can control
infection for prolonged periods of time in mice, macaques and
humans (Bar-On et al., 2018; Barouch et al., 2013; Horwitz
et al., 2013; Klein et al., 2012; Mendoza et al., 2018; Shingai
et al., 2013). Similarly, a fully protective vaccine will likely require
elicitation of bNAbs targeting multiple HIV-1 Env epitopes. This
highlights a need to identify and clinically develop antibodies to
new epitopes on the Env spike. Here, we studied the antibody
response of a long-term non-progressor, identifying bNAb
SF12 as part of a family of antibodies that target a glycan-
focused epitope on the silent face of gp120. While the silent
face of Env had not been considered a priority target for bNAbs
or for vaccine development, the discovery of potent and broad
antibodies such as SF12 suggests that targeting this site could
contribute to therapies and vaccines.
The cryo-EM structure of SF12 bound to B41 Env trimer
demonstrated that SF12 makes extensive contacts with N-gly-
cans at positions 262gp120, 295gp120 and 448gp120. While our
neutralization and structural data indicated that the PNGS at
295gp120 is dispensable for SF12 neutralization, we found the
highly conserved glycans at N262gp120 and N448gp120 to be
obligate contacts. Although SF12’s epitope is heavily glycan-
focused, the antibody also contacts the protein backbone of
Env, utilizing CDRHs 1 and 2 to mediate interactions at positions
293gp120, 444gp120 and 446gp120. In addition, SF12’s longer
CDRH3, as well as its different angle of Env approach relative
to VRC-PG05, allow SF12 to form additional protein contacts
at positions 59gp120, 214gp120, and 252gp120, which likely explain
the enhanced breadth and potency of SF12 compared to VRC-1524 Immunity 50, 1513–1529, June 18, 2019PG05, the only previously characterized antibody against the
Env silent face (Zhou et al., 2018).
Consistent with previous observations suggesting that the
N262gp120 glycan plays a crucial role in CD4-mediated viral entry
(Moore et al., 1994) and that the N448gp120 glycan (>85%
conserved) is less critical for viral infectivity (Behrens et al.,
2016; Falkowska et al., 2014), our in vivo studies showed loss
of N448gp120 as themajor escape pathway upon SF12 treatment.
Interestingly, the protein-protein contacts made by SF12 did not
contribute to routes of viral escape, which contrasts with HIV-1’s
dual mechanism of escape from VRC-PG05 by altering either the
N448gp120 glycan or the glycan-proximal residue E293gp120.
Indeed, viral evasion through alteration of the glycan shield or
sequence diversity dominates most bNAb epitopes (Falkowska
et al., 2014; Mouquet et al., 2012; Wagh et al., 2016; Walker
et al., 2009). Thus, SF12 may represent one of the few glycopep-
tide recognizing bNAbs where sequence variability at the pro-
tein-protein interface does not induce viral resistance to SF12
neutralization.
Despite the highly conserved N262gp120 and N448gp120 gly-
cans comprising its epitope, SF12 showed a gap in coverage
that could not be explained by the removal of the N448gp120
glycan alone. Computational analysis of data from a 119-isolate
viral panel suggested that glycosylation at position N442gp120
contributes to decreased SF12 breadth, likely through shielding
of the N262gp120 and N448gp120 glycans, making it more difficult
for SF12 to bind. SF12’s distinct epitope makes it potentially
useful for therapy or prevention as part of a combination of
bNAbs, particular in regions of the world with a high prevalence
of AE or B HIV-1 clades (both clades lack the N442gp120 glycan).
Indeed, the SF12 class of bNAbs is particularly potent and broad
against clade AE viruses, which represent a coverage gap of the
V3-glycan bNAbs, achieving 100% breadth and 10-fold
increased potencies compared with VRC01. Furthermore, given
its glycan-focused epitope, it may be possible to further improve
SF12/SF5 potency, breadth, and resistance to escape using
structure-based rational design as has been demonstrated for
other anti-HIV-1 bNAbs (Diskin et al., 2011, 2013; Rudicell
et al., 2014; Xu et al., 2017).
Our data support the hypothesis that evolutionary pathways to
silent face recognition are diverse. In addition to being isolated
from two different donors, SF12 and VRC-PG05 arose from
highly divergent VH (VH4-59*01 versus VH3-7*01) and VK genes
(VK3-20*01 versus VK4-1*01) (Lefranc et al., 2009). Moreover,
SF12 uses a long CDRH3 of 23 residues and a relatively short
CDRL3 of 6 residues, while VRC-PG05 uses a moderately long
17-residue CDRH3 and an average 8-residue CDRL3. Sequence
conservation between the CDR3s of the two antibodies is low
with no discernible motifs in common, which contrasts other
anti-HIV-1 bNAb families that show strong CDRH3 or CDRL3
length restrictions and/or recurring sequence motifs (McCoy
and Burton, 2017). In addition, SF12 shows an intermediate
rate of SHM compared with other HIV-1 bNAbs, with 21 and
19 amino acid substitutions in the heavy and light chains,
respectively. This rate of mutation is comparable to or lower
than rates found in V3-glycan patch antibodies, which are a
heavily pursued vaccination target with a similar breadth of
coverage (Escolano et al., 2017; McCoy and Burton, 2017).
Taken together, these differences illustrate the divergence of
solutions evolved by the SF12/SF5 and VRC-PG05 bNAbs to
target the silent face epitope, whereby SF12’s maturation gener-
ated an antibody capable of accommodating Env sequence
diversity at the protein surface.
In the context of eliciting silent face bNAbs, SF12 represents a
promising path forward based on its breadth, potency, and rela-
tively few SHMs. However, eliciting SF12-like bNAbs may face
some of the same hurdles as other potential Env target sites,
given its long CDRH3 and an insertion in CDRH2. In addition,
the SF12-Env structure revealed that, despite targeting non-
overlapping epitopes, SF12 binding induced a conformational
change in the N295gp120 glycan that affected binding of the V3-
glycan bNAb 10-1074. Thus, trimer-based immunogen design
strategies, such as those employed to elicit V3-glycan targeting
bNAbs (Escolano et al., 2017), should consider how alterations in
the glycan shield around the silent face glycan patch may pre-
vent maturation of SF12-like bNAbs.
Zhou et al. (2018) estimated VRC-PG05-like bNAbs are pre-
sent in 10% of individuals in a 38-donor cohort. It is possible
that SF antibodies were missed in previous studies, since the
focus was on isolating antibodies to well-characterized epi-
topes. In particular, protein-based sorting strategies might not
have allowed identification of these antibodies as also seen in
this study, in which only two members of the clone were isolated
by sorting using BG505 Env trimer as bait.
In summary, our results show that the glycan-rich silent face of
HIV-1 Env can be targeted by bNAbs with potencies and
breadths approaching those of antibodies against some of the
more well-characterized epitopes. Overall, our findings extend
current understanding of the recognition of glycan-focused epi-
topes on HIV-1 Env and expand the armamentarium of bNAbs
available for HIV-1 therapy, prevention, and immunogen design.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Donor 27845 is an adult male who was diagnosed with HIV-1 in 1985. He was a study participant in Seattle Vaccine Unit Observa-
tional Protocols ‘‘Immune Determinants Favoring Non-Progression in HIV-1 Infection’’ and ‘‘Evaluation of HIV-Specific Immunolog-
ical and Virological Responses of HIV-1 Multiply-Exposed Seronegative Individuals’’ (P.I. MJ McElrath) at the Fred Hutchinson
Cancer Research Center and was followed from 1998 - 2006. Apart from an NIH interventional study during which Donor 27845
started and stopped anti-retroviral therapy (ART) from 1998-2001, the subject has been off ART. Samples for this study were ob-
tained from 2005 and 2006. During the time of follow-up, viral loads ranged from 35 – 23,300 copies/ml (median: 1,640 copies/ml)
and CD4+ T cell counts ranged from 291 to 1,000 cells/mm3 (median: 590 cells/mm3). Studies and procedures were approved
by the Fred Hutchinson Cancer Research Center Internal Review Board (FWA00001920). Samples for analysis were obtained under
protocol MNU-0628 approved by the Rockefeller University Institutional Review Board.
Humanized mice
NOD-Rag1null IL2rgnull (NRG)mice were purchased from The Jackson Laboratory, andwere subsequently bred andmaintained in the
Dezentrales Tierhaltungsnetzwerk Weyertal at University of Cologne. NRGmice were fed ssniff complete feed 1124 during breeding
and ssniff complete feed 1534 during maintenance, and kept under a 12 hr light/dark cycle with specific-pathogen-free (SPF)
conditions. To determine the pharmacokinetics of antibody SF12, 6-week old non-humanized NRG mice (n = 3 per antibody,
male and female mice in both groups) were injected intravenously via the tail-vein with 250 mg of antibody (SF12 or 3BNC117).
Mice were bled on days 1, 3, 6, 9 and 14 after injection from the facial vein into Z-Gel Serum tubes (Sarstedt). Serum levels were
determined using a previously described total IgG ELISA (Klein et al., 2012). Humanized mice for treatment experiments were
generated using a previously described protocol with slight modifications (Klein et al., 2012; Traggiai et al., 2004). In brief,
1-5 days old NRGmice were sublethally irradiated, and 3-6 hours later injected intrahepatically with CD34+ hematopoietic stem cells.
CD34+ cells were enriched by magnetic bead-based positive selection (Miltenyi) from PBMCs obtained from human cord blood and
by placental perfusion under a protocol approved by the ethics committee of the Medical Faculty of the University of Cologne
(protocol #16-110). All cord blood and tissue donors provided written informed consent. Humanization screening was performed
at 12 weeks post injection by flow cytometry as previously described (Klein et al., 2012). For treatment experiments, humanized
mice were infected with HIV-1YU2 (Zhang et al., 2002) (produced in 293T cells) intraperitoneally (Horwitz et al., 2013; Klein et al.,
2012). To determine viral loads, plasma viral RNA was measured using a quantitative PCR (qPCR) assay (Horwitz et al., 2013,
2017) based on pol using primers HIV-1 Pol region F 50-TAATGGCAGCAATTTCACCA-30 and HIV-1 Pol region R 50-GAATGC
CAAATTCCTGCTTGA-30, and probe 50-/56-FAM/CCCACCAAC/ZEN/ARGCRGCCTTAACTG/3IABkFQ/-30. The limit of accuracy ofImmunity 50, 1513–1529.e1–e9, June 18, 2019 e4
the assay (based on the standard curve used) was 384 copies/ml. Plasma viral loads were determined twice before experiment start
and onlymicewith viral loads over 4,000 copies/ml were included in experiments. Male and femalemice (18-67 weeks old) were used
for treatment experiments. Treatment groupswerematched primarily based on viral load and stem cell donor (previously identified as
key determinants of viral load kinetics), with equal or comparable distributions of age and sex across groups. For antibody treat-
ments, 1 mg of each antibody was administered subcutaneously as a loading dose followed by twice-weekly injections of 0.5 mg
of each antibody in PBS subcutaneously for a total of 3 weeks (monotherapy) or 5 weeks (tri-mix). All mouse experiments were autho-
rized by the State Agency for Nature, Environment and Consumer Protection (LANUV) of North Rhine-Westphalia.
Cell lines
HEK293T cells were obtained from the American Type Culture Collection (ATCC) and maintained in Dulbecco’s modified Eagle
Medium (DMEM, GIBCO) with 10% fetal bovine serum (FBS, Sigma Aldrich), 1x Penicillin/Streptomycin (GIBCO), 1 mM Sodium
Pyruvate (GIBCO), 2 mM L-Glutamine (Thermo Fisher Scientific) at 37C/5% CO2. The HeLa-derived TZM-bl reporter cell line was
sourced from the NIH AIDS Reagent Program andmaintained in DMEM containing 10% fetal bovine serum, 1 mM Sodium Pyruvate,
2 mM L-Glutamine (Thermo Fisher Scientific), 50 mg/ml Gentamicin (Sigma-Aldrich), and 25mMHEPES (Biochrom) at 37C/5%CO2.
HEK293EBNA1-6E (293-6E) cells were obtained from the National Research Council Canada (NRC) and maintained in Freestyle 293
ExpressionMedium (Thermo Fisher Scientific) containing 0.2%Penicillin/Streptomycin at 37C /5%CO2with shaking at 90-120 rpm.
The sex of these cell lines is unknown. CHO Flp-InTM cells (Invitrogen) were a kind gift from the lab of John Moore (Cornell University)
and maintained in Ham’s F-12 Medium supplemented with 10% heat-inactivated FBS (Sigma-Aldrich), 200 U/ml penicillin/strepto-
mycin, 2 mM L-glutamine, 20 mM HEPES, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate (GIBCO), and further supple-
mented with 100 mg/ml Zeocin (Invitrogen).
METHODS DETAILS
IgG isolation for polyclonal IgG neutralization testing
IgG from subject 27845 was purified from heat-inactivated (1h 56C) plasma (late 2005 time point) using Protein G Sepharose 4 Fast
Flow (GE Healthcare), buffer exchanged into phosphate buffered saline (PBS) using an Amicon Ultra 30 kDa (Millipore), and sterile-
filtered.
Neutralization fingerprinting analysis
Neutralization fingerprinting (Figure 1B) of the polyclonal antibody response of subject 27845 was done using a panel of 20 diverse
HIV-1 strains (Doria-Rose et al., 2017). In brief, the neutralization fingerprint of a serum/polyclonal IgG (the potency-defined pattern of
neutralization of a set of diverse viral strains) is represented as a combination of the neutralization fingerprints of a reference set of
bNAbs, grouped in ten epitope-specific clusters. Using this method, the prevalence of each of the ten antibody groups can be
estimated for the given serum/polyclonal IgG, with prevalence scores ranging between 0 (low) and 1 (high). Additionally, two mea-
sures (Residual score and Median of scores) are computed as a way to estimate prediction confidence for the prevalence scores
(Georgiev et al., 2013; Raju et al., 2019). For neutralization fingerprinting of monoclonal antibodies (Figure 1F), a set of 80 viruses
for which data was available for all antibodies was used. The tree was constructed with a distance metric based on the similarity
of the neutralization patterns of the different antibodies. First, the correlations between the neutralization fingerprints (the
antibody-specific pattern of neutralization of a set of diverse HIV-1 strains) were computed for each pair of antibodies. The
antibody-antibody correlation matrix was then used as input to a hierarchical clustering algorithm to generate a neutralization
fingerprinting-based antibody tree. Generally, antibodies that cluster closely together in the tree may indicate similar patterns of
neutralization sensitivity/resistance for the given set of strains.
B cell microculture
Sorting and culturing of memory B cells was performed according to a previously published protocol (Doria-Rose et al., 2015; Huang
et al., 2013). In brief, peripheral bloodmononuclear cells (PBMCs) were stained with LIVE/DEAD Fixable Aqua (Invitrogen), CD19-PE-
Cy7, CD16-Pacific Blue, CD3-APC-Cy7, IgM-PE-Cy5 and IgD-FITC. Gating was done on IgM- and IgD- negative B cells, and these
were bulk sorted using a FACS Aria II cytometer. Bulk B cells were then diluted and plated at 2 B cells per well in 384-well plates.
B cells were cultured for two weeks in the presence of IL-2 (Roche), IL-21 (Life Technologies) and CD40L-expressing NIH 3T3 cells
as described (Doria-Rose et al., 2015; Huang et al., 2013). To assess culture success, a total IgG ELISA was performed on
supernatants after two weeks of culture to determine the number of wells with positive IgG production. Cell supernatants were
then screened in a microneutralization TZM.bl assay against viruses BaL.26 and BG505.T332N. Wells with neutralization > 50%
against one or both strains were amplified using various sets of previously described primer sets for heavy chain and light chain
(Doria-Rose et al., 2015; Scheid et al., 2011). Clone specific primers in the leader region were designed when necessary to obtain
fully native sequences of the entire framework 1 region (FWR1). Positive bands were sanger sequenced using reverse amplification
primers. In the case that multiple B cells were present (double peaks were obtained), bands were subcloned using the TOPO-TA kit
(Invitrogen), colony PCR was performed, and bands were again sequenced by Sanger sequencing. Antibody sequences were
analyzed using both IgBLAST and the international ImMunoGeneTics information system (IMGT) (Lefranc et al., 2009; Ye et al.,
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ligation independent cloning (SLIC) (Jeong et al., 2012; Tiller et al., 2008; von Boehmer et al., 2016). The correct heavy and light chain
pairing of the SF5/SF12 antibody family was confirmed by single B cell BG505 bait sorting data.
Single B cell bait-sorting
BG505 SOSIP.664-Avi for B cell sorting was produced in CHO cells and purified using a PGT145 immunoaffinity column as described
(Pugach et al., 2015; Sok et al., 2014). Biotinylation of BG505 was done using BirA-ligase (Avidity) according to the manufacturer’s
instructions. An aliquot of BG505 SOSIP.664-Avi-biotin was freshly coupled to Streptavidin-PE (Invitrogen) using 2.5 mg and 1 ml
(0.2 mg/ml) of Streptavidin-PE in a total volume of 10 ul PBS. For the sort, 20 million PBMCs were freshly thawed and stained
with the following fluorophore-coupled anti-human antibodies: IgG-APC, IgM-BV605, CD19-BV421, CD20-BV421, CD3-PerCP-
Cy5.5, CD14 PerCP-Cy5.5, CD335 PerCP-Cy5.5, CD606 PerCP-Cy5.5 and 1:20 Streptavidin-PE coupled BG505.SOSIP.664 mix
described above. Staining was performed for 30 mins at 4C. Sorting was done on a FACS Aria II. The gating first included singlets,
followed by exclusion of unwanted cells (CD3-, CD14-, CD335-, CD606-), selection for B cells (CD19+, CD20+) and finally sorting of
single IgG+ PE+ cells into 96-well plates containing lysis buffer. B cell antibody genes were amplified and Sanger sequenced. Anti-
body sequences were analyzed using both IgBLAST and the international ImMunoGeneTics information system (IMGT) (Lefranc
et al., 2009; Ye et al., 2013). Sequences of interest were cloned into human Igg1-, Igk or Igl-expression vectors by SLIC as described
above.
Phylogenetic analysis of SF family heavy chain sequences
The IgVH4*59*01 Homo sapiens allele sequence was obtained from the international ImMunoGeneTics information system (IMGT)
(Lefranc et al., 2009). Antibody heavy chain nucleotide sequences of the SF family were aligned with the IgVH4*59*01 sequence in
Geneious R8 (v8.1.9) using ClustalW. The maximum-likelihood tree was generated using the RAxML plugin (v 7.2.8) with a GTR
Gamma model using the ‘Rapid Bootstrapping and search for best-scoring ML tree’ function with 100 bootstrap replicates. The
best-scoring ML tree was then formatted using FigTree (v1.4.3).
Antibody production for ELISA, neutralization assays and in vivo experiments
293-6E cells were maintained in Freestyle 293 Expression Medium (Thermo Fisher Scientific) containing 0.2% Penicillin-Strepto-
mycin (Thermo Fisher Scientific). Paired heavy and light chain expression constructs were transfected into 293-6E cells (NRC) using
branched polyethylenimine (PEI) 25 kDA (Sigma). After 7 days of culture, cells were spun down at 4200 g for 40 mins at 4C and
supernatants were filtered through 0.22 mM aPES (Thermo Nalgene Rapid-Flow). Antibodies were then purified from filtered super-
natants using Protein G Sepharose 4 Fast Flow (GE Healthcare) according to standard protocols. Antibodies were buffer exchanged
and concentrated into PBS using Amicon Ultra centrifugal filter (Millipore) with either a 30 or 50 kDAmolecular weight cutoff (MWCO).
Enzyme-linked immunosorbent assay (ELISA) of (mutant) YU2 gp120/gp140 proteins
Wild-type and mutant His-tagged YU2 gp120/gp140 proteins were expressed by transient transfection of 293-6E cells and purified
usingNi-NTA according tomanufacturer’s instructions. Corning Costar 96-Well Assay high-binding plates were coated for 1h at 37C
with 2 mg/ml of the respective protein (YU2 gp120WT, YU2 gp120 D368Rgp120, YU2 gp120 N332Agp120, YU2 gp120 N160Kgp120 and
YU2 gp140WT, YU2 gp140 A281Tgp120/D368Kgp120, YU2 gp140 N160Kgp120 A281Tgp120/D368Kgp120 and N332Kgp120 (triple mutant))
using a volume of 50 ml/well. Plates were washed 6x using PBS-Tween20 (0.05%), and subsequently blocked using 3% BSA in
PBS for 1h at 37C (200 ml/well). After washing, serially-diluted antibodies were added (starting at 4 or 10 ug/ml, 1:3 dilution series)
at 50 ml/well in 1% PBS/BSA and incubated for 1h at room temperature or 37C. After another wash step, anti-human IgG (Southern
Biotech or Jackson Immunoresearch) was added at 1:5000 (50 ml/well) in 1% PBS/BSA for 30 mins at 37C. Development was done
using 100 ml/well ABTS 1-Step Solution (Thermo Fisher Scientific), and absorbance wasmeasured at 405 nm on a FluoStar Omega or
415 nm on a Tecan Sunrise.
BG505 SOSIP.664-His ELISAs
Corning Costar 96-Well Assay high-binding plates were coated overnight at room temperature or for 1h at 37Cwith 2 mg/ml anti-His-
tag antibody (Abcam) in PBS (50 ml/well). Plates were washed 6x using PBS-Tween20 (0.05%), and subsequently blocked using 3%
BSA in PBS or 2% milk powder in PBS for 1h at 37C (200 ml/well). After washing, purified BG505 SOSIP.664-His (de Taeye et al.,
2015; Sanders et al., 2013) was added at 2 mg/ml in 1% BSA in PBS (50 ml/well), and incubated for 1h at 37C, followed by another
washing step. Next, serially-diluted antibodies were added (starting at 4 or 10 ug/ml, 1:3 dilution series) at 50 ml/well in 1%PBS/BSA,
and incubated for 1h at room temperature or 37C. After washing, anti-human IgG (Southern Biotech) was added at 1:5000 in 1%
BSA in PBS (50 ml/well) for 30 mins at 37C. Post washing, development was done using 100 ml/well ABTS 1-Step Solution (Thermo
Fisher Scientific), and absorbance was measured at 405 nm on a FluoStar Omega or 415 nm on a Tecan Sunrise.
Competition ELISAs
Antibodies SF5 and SF12 were biotinylated using the FluoReporter Mini-Biotin-XX Protein Labeling Kit (Thermo Fisher Scientific).
Corning Costar 96-Well Assay high-binding plates were coated overnight at room temperature or for 1h at 37C with 2 mg/ml anti-
His-tag antibody (Abcam) in PBS (50 ml/well). Plates were washed 6x using PBS-Tween20 (0.05%), and subsequently blocked using
3% BSA in PBS for 1h at 37C (200 ml/well). After washing, BG505 SOSIP.664 was added at 2 mg/ml in 1% BSA in PBS (50 ml/well),Immunity 50, 1513–1529.e1–e9, June 18, 2019 e6
and incubated for 1h at 37C, followed by another washing step. Next, serially-diluted competitor antibodies (starting at 32 mg/ml, 1:3
dilution series) were added at 50 ml/well in 1% PBS/BSA and incubated for 1h at room temperature. Plates were washed and
biotinylated SF5 or SF12 were added at 0.5 mg/ml (50 ml/well in 1% PBS/BSA) and incubated for 1h room temperature. After another
wash step, Streptavidin-HRP (1:1000) was added at 50 ml/well in 1% PBS/BSA for 30 mins at room temperature. Development was
done using 100 ml/well ABTS 1-Step Solution (Thermo Fisher Scientific), and absorbance was measured at 405 nm on a FluoStar
Omega or 415 nm on a Tecan Sunrise.
Generation of mutant HIVYU2 and HIVBG505 pseudoviruses
Point mutations were introduced into the HIVYU2 and HIVBG505T332N gp160 expression plasmids using the QuikChange site-directed
mutagenesis kit (Agilent Technologies) or the Q5 Site-directed mutagenesis kit (NEB) according to manufacturer’s specifications.
Pseudoviruses were produced by co-transfection with pSG3DEnv into HEK293T according to an established protocol (Sarzotti-Kel-
soe et al., 2014).
In vitro neutralization assays
Neutralization activities of polyclonal IgG and monoclonal antibodies were determined using a luciferase-based TZM.bl assay (Li
et al., 2005; Sarzotti-Kelsoe et al., 2014; Seaman et al., 2010), which measures the reduction of Tat-induced luciferase expression
in TZM-bl reporter cells during a single round of infection. Samples were assayed at least in in duplicate. Polyclonal IgG neutralization
assays were done using a starting concentration of 500 mg/ml andmonoclonal antibodies were assayed at starting concentrations of
10, 25 or 50 mg/ml. IC50s and IC80s were derived 5-parameter curve fitting. Neutralization was also assessed against murine leukemia
virus (MuLV) to detect unspecific activity (Sarzotti-Kelsoe et al., 2014). Neutralization data for Figures 1E and 2E were analyzed and
graphed using Antibody Database (v 2.0) (West et al., 2013).
Autoreactivity and polyreactivity assays
Autoreactivity of antibodies SF5 and SF12 and reference antibodies 4E10 and 2F5 was determined using the commercially-available
HEp-2 based assay NOVA Lite kit (Inova Diagnostics) at an IgG concentration of 25 mg/ml. Slides were photographed on a Leica DMI
6000 Bwith an exposure of 800ms, Gain of 10 and Intensity of 100%.Measurements were done in duplicate. Representative images
are shown in Figure S1.
Polyreactivity assays were conducted using ELISA detection of non-specific binding to baculovirus extracts as described (Ho¨tzel
et al., 2012). Briefly, a solution of 1% baculovirus particles in 100mM sodium bicarbonate buffer pH 9.6 was absorbed onto the wells
of a 384-well ELISA plate (NuncMaxisorp) using a Tecan FreedomEvo liquid handling robot, and the plate was incubated overnight at
4C. The plate was then blockedwith 0.5%BSA in PBS for 1 hour at room temperature. Purified IgGs (diluted to 1 mg/mL in PBS, 0.5%
BSA) were added to the blocked assay plate and incubated for 3 hours at room temperature. Bound IgG was detected as the
luminescence signal at 425 nm using an HRP-conjugated anti-human IgG (H&L) secondary antibody (Genscript) and SuperSignal
ELISA Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific).
Single genome sequencing of plasma HIV-1 Env genes
Amplification of genes encoding HIV-1 Env gp160 from single viral genomes was carried out as described previously with slight
modifications (Keele et al., 2008; Salazar-Gonzalez et al., 2008). In brief, complementary DNA (cDNA) was synthesized using primer
YB383 50-TTTTTTTTTTTTTTTTTTTTTTTTRAAGCAC-30 and Superscript III (Invitrogen) according to manufacturer’s instructions.
cDNAwas then serially diluted andHIV-1 Envwas amplified in two rounds of nested PCRusing PlatinumTaqGreenHot Start (Thermo
Fisher Scientific) and primers specifically adapted for HIVYU2NL4-3 (1
st round primers were YB383 and YB50 50- GGCTTAGGCAT
CTCCTATGGCAGGAAGAA-30 ; 2nd round primers YB49 50-TAGAAAGAGCAGAAGACAGTGGCAATGA-30, YB52 50-GGTGTG
TAGTTCTGCCAATCAGGGAAGWAGCCTTGTG-30). Positive Bands from amplifications with less than 30% efficiency were PCR-
purified using the Nucleospin Gel and PCR-Clean Up kit (Macherey Nagel) and Sanger sequenced using a set of 8 primers. Env se-
quences were assembled using the Geneious 8.1.9 (Biomatters) de-novo assembly tool. Assembled sequences were cross-checked
against sequencing traces again to validate assemblies, and sequences with full coverage of gp160 Env were used in downstream
analyses.
Protein expression and purification for structural studies
Fabs fromSF12, SF5 and 10-1074 IgGswere produced as described (Scharf et al., 2015). Briefly, Fabswere expressed by transiently
transfecting HEK293-6E cells with vectors encoding the appropriate light chain and C-terminal 6x-His tagged heavy chain genes.
Secreted Fabs were purified from cell supernatants using Ni2+-NTA affinity chromatography (GE Healthcare), followed by size exclu-
sion chromatography (SEC) with a Superdex200 16/60 column (GE Healthcare). Purified Fabs were concentrated and maintained at
4C in storage buffer (20 mM Tris pH 8.0, 150 mM NaCl, 0.02% sodium azide).
A gene encoding soluble B41SOSIP.664gp140 trimer, including SF501Cgp120, T605Cgp41, and I559Pgp41 substitutions, an enhanced
gp120–gp41 cleavage site (REKR to RRRRRR), and a stop codon after residue 664gp41 (Env numbering according to HXB2 nomencla-
ture), was stably expressed in Chinese hamster ovary cells as described (Chung et al., 2014; Pugach et al., 2015). Secreted Env trimers
expressed in the absence of glycosylation inhibitors were isolated from cell supernatants using 2G12 immunoaffinity chromatography
by covalently coupling 2G12 IgGmonomer to an activated-NHSSepharaose column (GEHealthcare) as described (Scharf et al., 2015).e7 Immunity 50, 1513–1529.e1–e9, June 18, 2019
Trimers were eluted using 3M MgCl2 and immediately dialyzed into storage buffer before SEC purification with a Superdex200 16/60
column (GEHealthcare) against the same buffer. Peak fractions pertaining to SOSIP trimers were pooled and repurified using the same
column and buffer conditions. Individual fractions were stored separately at 4C.
Crystal structure of SF12 Fab
Purified Fab was concentrated to 10-15 mg/mL by centrifugation with a 30-kDa concentrator (Amicon). Initial matrix crystallization
trials were performed at room temperature using the sitting drop vapor diffusion method by mixing equal volumes of protein sample
and reservoir using a TTP LabTechMosquito robot and commercially-available screens (Hampton Research andQIAGEN). Initial hits
were optimized and crystals were obtained in 0.1 M HEPES pH 7.0, 1.6 M Sodium Formate at 20C. Crystals were cryo-protected
stepwise to 3.0 M Sodium Formate before being cryopreserved in liquid nitrogen.
X-ray diffraction data were collected for SF12 Fab at the Stanford Synchroton Radiation Lightsource (SSRL) beamline 12-2 on a
Pilatus 6M pixel detector (Dectris). Data from a single crystal were indexed and integrated in XDS (Kabsch, 2010) and merged with
AIMLESS in the CCP4 software suite (Winn et al., 2011). Structures were determined by molecular replacement in PHASER (McCoy
et al., 2007) using a single search with coordinates of the F105 Fab (PDB 1U6A), which had 85% sequence identity to SF12 after
removal of CDR loops. Models were refined using B-factor refinement in CNS (Brunger, 2007) and Phenix (Adams et al., 2010),
followed by several cycles of manual building with B factor sharpening in Coot (Emsley et al., 2010).
Cryo-EM sample preparation
Complexes of B41-SF12-101074 were assembled by incubating purified SF12 Fab with B41 SOSIP.664 trimer at a 1.2:1 Fab:gp120-
protomer molar ratio. Following overnight incubation at RT, 10-1074 Fab was incubated with the complex at a 1.2:1 Fab:gp120-
protomer molar ratio for 5 h. SF12–B41–10-1074 complexes were diluted to 0.5-0.8 mg/ml in TBS and 3mL was added to Quantifoil
R2/2 300 mesh copper grids (Electron Microscopy Services) that had been freshly glow-discharged using a PELCO easiGlow (Ted
Pella). Samples were immediately vitrified in 100% liquid ethane using a Mark IV Virtoblot (Thermo Fisher Scientific) by blotting for
2.5-4 s with Whatman No. 1 filter paper at 20C and 100% relative humidity.
Cryo-EM data collection and processing
Single-particle cryo-EM data were collected on a Titan Krios transmission electron microscope (Thermo Fisher Scientific) operating
at 300 kV, using the EPU automated image acquisition software (Thermo Fisher Scientific). Movies were collected on a Gatan K2
Summit direct electon detector (DED) operating in counting mode at a nominal magnification of 130,000x (1.09 A˚/pixel) using a
defocus range of1.2 mm to3.0 mm.Movies were collected over an 8 s exposure with an exposure rate of4.8 e- /pixel/s, resulting
in a total dose of 40 e-/A˚2.
Movies were motion corrected and doseweighted using the MotionCor2 frame alignment program in RELION-3 (Zivanov et al.,
2018). Non-doseweighted summed images were used for CTF determination using Gctf (Zhang, 2016), and reference-free particle
picking from 18micrographs was achieved using Laplacian-of-Gaussian filtering in RELION-3 (Zivanov et al., 2018). An initial stack of
1,907 particles was 2D classified and the best classes representing top-down and side views of Env-trimers was used for subsequent
automated template-based picking in RELION-3. 676,161 particles were extracted from 2,209 dose-weighted micrographs, binned
4x4 (4.36 A˚/pixel), and subjected to reference-free 2D classification in RELION-3 and a 240 A˚ circular mask. A total of 371,665
particles corresponding to class averages that displayed secondary-structural elements and represented views different views of
Fab bound Env-trimer were extracted and re-centered prior to heterogenous ab inito model generation using cryoSPARC v2.2
(Punjani et al., 2017).
The generated volumewas low-passed filtered to 40 A˚ and used as an initial model for 3D auto-refinement in RELION-3. Due to the
observed low occupancy of 10-1074 Fab, particles were re-extracted unbinned (1.09 A˚/pixel) and 3D classified (C1 symmetry, k = 8)
with a soft mask generated from the initial model (5-pixel extension, 10-pixel soft cosine edge). Classification resulted in two distinct
classes comprising three or two SF12 Fabs bound per trimer and one 10-1074 Fab bound per trimer. Particles from each class were
then separately refined, followed by 3D auto-refinement using a soft mask in which Fab constant domains were masked out. Class 1
(301,920 particles) refined to a final estimaled resolution of 3.28 A˚ (SF123—B41–10-10741; C1 symmetry) and class 2 (55,136
particles) refined to a final estimated resolution of 4.36 A˚ (SF122—B41–10-10741; C1 symmetry) according to gold-standard
FSC (Bell et al., 2016).
Modeling and refinement of cryo-EM structures
For the final reconstruction of class 1 (SF123—B41–10-10741; C1 symmetry), initial coordinates were generated by docking reference
models into the cryo-EM density using UCSF Chimera v1.13 (Goddard et al., 2007) (gp120-gp41, PDB 6CH9; 10-1074 Fab, PDB
4FQQ; SF12 Fab, this work). Initial models were then refined into the EM maps using one round of rigid body, morphing, and
simulated annealing followed by subsequent rounds of B-factor refinement in Phenix (Adams et al., 2010). Models were manually
built following iterative rounds of real-space and B-factor refinement in Coot (Emsley et al., 2010) and Phenix (Adams et al., 2010)
with secondary structure restraints. Modeling of glycans was achieved by interpreting cryo-EM density at PNGS in Coot using a
mapwith a75 A˚2 B-factor sharpening value, contoured at 6s due to the lower resolution of glycans at the periphery of the structure.
Validation of model coordinates was performed using MolProbity (Chen et al., 2010) and Privateer (Agirre et al., 2015).Immunity 50, 1513–1529.e1–e9, June 18, 2019 e8
Structural and bioinformatic analyses
Superpositions and figures were rendered using PyMOL (Version 1.5.0.4 Schrodinger, LLC), and protein electrostatic calculations
were done using APBS and PDB2PQR webservers (Unni et al., 2011). Buried surface areas (BSAs) were determined with PDBePISA
using a 1.4A˚ probe (Krissinel and Henrick, 2007). Potential hydrogen bonds were assigned using a distance of < 3.6A˚ and an A-D-H
angle of > 90, while the maximum distance allowed for a van der Waals interaction was 4.0A˚. Putative H-bonds, van der Waals
assignments and total BSA should be considered tentative, owing to the relatively low structure resolutions. Computational analysis
of neutralization panel data (Table S7) was done as previously described (West et al., 2013). For determining the difference in
orientation of the antibody variable domains of the SF12-Env and VRC-PG05-Env complexes, those structures were aligned on
gp120, and then the transformation relating the VH-VL domains was calculated by using TM-align (Zhang and Skolnick, 2005).
The corresponding screw transformation was calculated as described (Siciliano and Khatib, 2008) and visualized using Antibody
Database (West et al., 2013).
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the nucleotide sequences of SF-family members are GenBank: MK722158–MK722171. The accession
numbers for the cryo-EM reconstructions of the SF12–B41–10-1074 complexes comprising three or two SF12 Fabs are Electron
Microscopy Data Bank (EMDB): EMD-20100 and EMD-20101, respectively. The accession numbers for coordinates for atomic
models of the cryo-EM SF12–B41–10-1074 complex (class 1: three SF12 Fabs and one 10-1074 Fab) and the unliganded SF12
Fab crystal structure are Protein Data Bank (PDB): PDB 6OKP and PDB 6OKQ, respectively.e9 Immunity 50, 1513–1529.e1–e9, June 18, 2019
